Moleculin Biotech, Inc.(MBRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MBRX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Moleculin Biotech, Inc. (MBRX), a Healthcare sector company. MBRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Moleculin Biotech, Inc. reports net income of $-12.8M, free cash flow of $-6.1M. Top institutional holders of MBRX by reported 13-F value include SABBY MANAGEMENT,, GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MBRX trades on the Nasdaq exchange and files with the SEC under CIK 1659617. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MBRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Moleculin Biotech, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$0.00
Net Income
Q1 2026
$-12.8M
Free Cash Flow
Q1 2026
$-6.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
-28.8% YoYOperating Income
+5.8% YoYTotal Assets
+30.7% YoYOp. Cash Flow
+4.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $-33.6M -28.8% | $-26.0M +12.5% | $-29.8M -87.3% | $-15.9M +8.4% | $-17.4M -77.0% | $-9.8M |
| Operating Income | $-25.1M +5.8% | $-26.6M +10.1% | $-29.6M -29.0% | $-23.0M -16.3% | $-19.7M -128.2% | $-8.7M |
| Total Assets | $22.1M +30.7% | $16.9M -55.7% | $38.2M -54.6% | $84.1M +189.7% | $29.0M +49.0% | $19.5M |
| Operating Cash Flow | $-22.7M +4.7% | $-23.9M -1.1% | $-23.6M -24.5% | $-19.0M -6.6% | $-17.8M -142.6% | $-7.3M |
AI Insight: MBRX Financial Trends
Pre-revenue biotech burning cash consistently with volatile equity swings; Q4 2025 one-time gain masks ongoing operating losses.
• Revenue remains at $0M across all periods; company is pre-commercialization with no product sales.
• Operating income negative every quarter, ranging $-5M to $-8M; no improvement trajectory visible.
• Q4 2025 net income of $16M appears to be one-time gain (possibly asset sale or accounting adjustment); Q1 2026 reverted to $-13M loss.
• Equity swung from $-27M in Q3 2025 to $15M in Q1 2026, suggesting significant capital raise or revaluation event.
⚠ Operating cash flow negative every quarter ($-5M to $-7M); runway depletion without revenue inflection is critical risk.
⚠ Equity turned negative in Q2–Q3 2025; company likely required dilutive financing to restore balance sheet in Q4 2025.
AI Insight: MBRX Ratio Trends
Data insufficient to assess trends—only ROE available for three quarters, all deeply negative, with no margin, cash flow, or leverage metrics reported.
• ROE deteriorated from -154.0% in Q2 2024 to -186.7% in Q1 2025, signaling sustained shareholder value destruction.
⚠ No OpMargin, NPM, ROA, ROIC, or D/E data across all periods—unable to assess profitability path or balance-sheet health.
⚠ Consecutive quarters of triple-digit negative ROE suggest ongoing losses relative to equity base.
Get alerted when MBRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Moleculin Biotech, Inc. including:
Top Institutional Holders of MBRX
SABBY MANAGEMENT, LLC
$171.8K75,021 shGEODE CAPITAL MANAGEMENT, LLC
$74.0K32,329 shVANGUARD CAPITAL MANAGEMENT LLC
$31.8K13,869 shVANGUARD FIDUCIARY TRUST CO
$13.9K6,072 shRockefeller Capital Management L.P.
$10.1K4,421 shUBS Group AG
$7.8K3,409 shTower Research Capital LLC (TRC)
$4.2K1,835 shBlackRock, Inc.
$1.1K491 shEFG International AG
$994.00434 shPinnacle Wealth Planning Services, Inc.
$643.00281 sh
| Fund | Value | Shares |
|---|---|---|
| SABBY MANAGEMENT, LLC | $171.8K | 75,021 |
| GEODE CAPITAL MANAGEMENT, LLC | $74.0K | 32,329 |
| VANGUARD CAPITAL MANAGEMENT LLC | $31.8K | 13,869 |
| VANGUARD FIDUCIARY TRUST CO | $13.9K | 6,072 |
| Rockefeller Capital Management L.P. | $10.1K | 4,421 |
| UBS Group AG | $7.8K | 3,409 |
| Tower Research Capital LLC (TRC) | $4.2K | 1,835 |
| BlackRock, Inc. | $1.1K | 491 |
| EFG International AG | $994.00 | 434 |
| Pinnacle Wealth Planning Services, Inc. | $643.00 | 281 |
More Healthcare Companies
View all Healthcare →Put MBRX on your watchlist
Track score changes the day Moleculin Biotech, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MBRX a good stock to buy?
13F Pro's AI-powered analysis of Moleculin Biotech, Inc. (MBRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MBRX are available on the MBRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MBRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MBRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Moleculin Biotech, Inc.'s investment landscape.